Search Results

DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

DisperSol Technologies, LLC, a specialty pharmaceutical company, today announced the appointment of Tim Scott as president and chief executive officer (CEO) of the company.

DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.

DisperSol Technologies LLC announced today that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies.

DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.

In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.

In this episode presented by PII, BioSpace’s head of insights discusses decentralized clinical studies and how connected technology can improve patient compliance with guests Oliver Eden and Travis Webb.

DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar